Satellos Bioscience Inc (MSLE)

$11.25 -0.66 (-5.54%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 105,000
Avg Vol 15,576
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 39%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a li...

Industry: Biotechnology
Sector: Healthcare
Address:
Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
nnnuuu
nnnuuu Jul. 21 at 5:08 PM
$MSLE should be trading at $55/share. Was investigating the stock a bit more. contextually, i believe this will be ready for accelerated approval, together with orphan drug. i also saw a letter about $CAPR adcom where the physician scientists arguedthe intended primary for the HOPE ph3 being upper limb function (PUL) and not to be hypercritical about the deramiocel data on cardiomyopathy. if we compare the current status of these two drugs purely along this axis of upper limb function, where deramiocel does not actually regenerate muscle but SAT-3247 does, i see no reason why Satellos could not be trading at similar levels to CAPR (1.1bn mkcap). that is a 6.32x premium from here. $8.75 x 6.32 = $55
2 · Reply
citywokowner
citywokowner Jul. 21 at 12:26 PM
$MSLE time for a rip?
0 · Reply
Merlintrader
Merlintrader Jul. 18 at 7:36 PM
$MSLE Satellos Bioscience ($MSLE): SAT-3247, BASECAMP, TRAILHEAD and the Q4 2026 Readouts https://www.merlintrader.com/satellos-bioscience-stock-hub/
0 · Reply
StreetwiseReports
StreetwiseReports Jul. 15 at 4:17 PM
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win https://ow.ly/8xUG50ZnTgm Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity. $MSCL.TO $MSLE
0 · Reply
StreetwiseReports
StreetwiseReports Jul. 14 at 10:39 PM
Biotech With Muscle Disease Drug Uncovers Results in Trial Data https://ow.ly/o2BL50ZnzHQ Satellos Bioscience Inc. ( $MSCL.TO $MSLE ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.
0 · Reply
spaceodyssey2001
spaceodyssey2001 Jul. 12 at 7:16 PM
$MSLE Current fair market value is $20 - $25 at the low end
0 · Reply
nnnuuu
nnnuuu Jul. 12 at 4:25 PM
$MSLE hard not to overstate how important the cluster of improvements were in this small data set: 1. Effort increased 2. Strength stabilised 3. MRI fat fraction decreased 4. Creatine kinase (CK) decreased CK decrease can happen in young adult populations anyway if the muscle bulk gets replaced with fat/fibrosis, since muscle cell death leaks CK into the blood. Since CK decreased WITH MRI-FF reduction and strength improvements, it means the clinical outcomes are almost certainly due to the drug. Strong confidence going into 2H26 for MSLE.
1 · Reply
spaceodyssey2001
spaceodyssey2001 Jul. 12 at 3:26 PM
$MSLE The six month Phase 2 TRAILHEAD data showed that 100% of adult DMD participants experienced a decline in muscle fat fraction. This indicates a complete reversal of the natural history of the disease where fat typically replaces muscle tissue. The FDA recently granted SAT-3247 Fast Track, Orphan Drug, and Rare Pediatric Disease designations. These statuses shorten approval timelines. They also grant a lucrative Priority Review Voucher (worth about $200 million USD on the open market) upon success. Wall Street views the equity as heavily discounted. Top-tier healthcare firms like Guggenheim, Leerink, and H.C. Wainwright maintain Strong Buy ratings. Their price targets range from $18.00 to $40.00 (Cantor risk-adj NPV $52/share, non-risk-adj NPV $409/share (includes FSHD)) representing immense upside from the current sub-$10 price point.
0 · Reply
spaceodyssey2001
spaceodyssey2001 Jul. 12 at 2:56 PM
$MSLE
0 · Reply
spaceodyssey2001
spaceodyssey2001 Jul. 12 at 2:01 PM
$MSLE According to Chen Lin of What is Chen Buying? What is Chen Selling? in a July 8 update, "MSLE delivered!" "The data couldn’t be better in my opinion," Chen wrote. "Not only did two patients improve significantly in the MRI, all the four patients are moving in the right direction. I believe if MSLE can deliver good data of the basecamp Q4 and continue improving trailhead data, accelerated approval should be achievable." Chen said he sees the company hitting US$100 per share "by the end of the year if the data are as good as we hope." "I have been there before and can see this happening if the data are positive," the expert said. "The market is giving less than 10% chance of success, I believe it is very mispriced." https://www.streetwisereports.com/article/2026/07/09/biotech-with-muscle-disease-drug-uncovers-results-in-trial-data.html
0 · Reply
Latest News on MSLE
Satellos price target raised to $18 from $11 at H.C. Wainwright

2026-07-09T10:10:22.000Z - 13 days ago

Satellos price target raised to $18 from $11 at H.C. Wainwright

Satellos announces Fast Track designation for SAT-3247

2026-06-29T11:15:42.000Z - 23 days ago

Satellos announces Fast Track designation for SAT-3247

Satellos resumed with a Speculative Buy at Canaccord

2026-05-21T11:18:01.000Z - 2 months ago

Satellos resumed with a Speculative Buy at Canaccord

Satellos reports Q1 EPS (53c), consensus (59c)

2026-05-15T12:06:36.000Z - 2 months ago

Satellos reports Q1 EPS (53c), consensus (59c)

Satellos initiated with a Buy at Guggenheim

2026-04-28T11:00:43.000Z - 3 months ago

Satellos initiated with a Buy at Guggenheim

Satellos initiated with an Outperform at Leerink

2026-04-06T10:41:27.000Z - 3 months ago

Satellos initiated with an Outperform at Leerink

Satellos has ‘catalyst-rich; 2026, says H.C. Wainwright

2026-03-30T10:21:50.000Z - 4 months ago

Satellos has ‘catalyst-rich; 2026, says H.C. Wainwright

Cantor starts Satellos with an Overweight on DMD therapy potential

2026-03-11T12:00:38.000Z - 4 months ago

Cantor starts Satellos with an Overweight on DMD therapy potential

Satellos initiated with an Overweight at Cantor Fitzgerald

2026-03-11T10:31:41.000Z - 4 months ago

Satellos initiated with an Overweight at Cantor Fitzgerald

Satellos Bioscience Inc. Common Stock trading resumes

2026-03-10T14:10:13.000Z - 4 months ago

Satellos Bioscience Inc. Common Stock trading resumes

Satellos Bioscience Inc. Common Stock trading halted, volatility trading pause

2026-03-10T14:05:15.000Z - 4 months ago

Satellos Bioscience Inc. Common Stock trading halted, volatility trading pause

Satellos presents interim SAT-3247 data at MDA Conference

2026-03-10T11:22:01.000Z - 4 months ago

Satellos presents interim SAT-3247 data at MDA Conference

Satellos price target raised to $40 from $5 at Oppenheimer

2026-02-10T13:12:15.000Z - 5 months ago

Satellos price target raised to $40 from $5 at Oppenheimer

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Feb 6, 2026, 8:30 AM EST - 5 months ago

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Satellos Bioscience IPO Registration Document (F-10)

Feb 5, 2026, 4:09 PM EST - 5 months ago

Satellos Bioscience IPO Registration Document (F-10)

nnnuuu
nnnuuu Jul. 21 at 5:08 PM
$MSLE should be trading at $55/share. Was investigating the stock a bit more. contextually, i believe this will be ready for accelerated approval, together with orphan drug. i also saw a letter about $CAPR adcom where the physician scientists arguedthe intended primary for the HOPE ph3 being upper limb function (PUL) and not to be hypercritical about the deramiocel data on cardiomyopathy. if we compare the current status of these two drugs purely along this axis of upper limb function, where deramiocel does not actually regenerate muscle but SAT-3247 does, i see no reason why Satellos could not be trading at similar levels to CAPR (1.1bn mkcap). that is a 6.32x premium from here. $8.75 x 6.32 = $55
2 · Reply
citywokowner
citywokowner Jul. 21 at 12:26 PM
$MSLE time for a rip?
0 · Reply
Merlintrader
Merlintrader Jul. 18 at 7:36 PM
$MSLE Satellos Bioscience ($MSLE): SAT-3247, BASECAMP, TRAILHEAD and the Q4 2026 Readouts https://www.merlintrader.com/satellos-bioscience-stock-hub/
0 · Reply
StreetwiseReports
StreetwiseReports Jul. 15 at 4:17 PM
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win https://ow.ly/8xUG50ZnTgm Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity. $MSCL.TO $MSLE
0 · Reply
StreetwiseReports
StreetwiseReports Jul. 14 at 10:39 PM
Biotech With Muscle Disease Drug Uncovers Results in Trial Data https://ow.ly/o2BL50ZnzHQ Satellos Bioscience Inc. ( $MSCL.TO $MSLE ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.
0 · Reply
spaceodyssey2001
spaceodyssey2001 Jul. 12 at 7:16 PM
$MSLE Current fair market value is $20 - $25 at the low end
0 · Reply
nnnuuu
nnnuuu Jul. 12 at 4:25 PM
$MSLE hard not to overstate how important the cluster of improvements were in this small data set: 1. Effort increased 2. Strength stabilised 3. MRI fat fraction decreased 4. Creatine kinase (CK) decreased CK decrease can happen in young adult populations anyway if the muscle bulk gets replaced with fat/fibrosis, since muscle cell death leaks CK into the blood. Since CK decreased WITH MRI-FF reduction and strength improvements, it means the clinical outcomes are almost certainly due to the drug. Strong confidence going into 2H26 for MSLE.
1 · Reply
spaceodyssey2001
spaceodyssey2001 Jul. 12 at 3:26 PM
$MSLE The six month Phase 2 TRAILHEAD data showed that 100% of adult DMD participants experienced a decline in muscle fat fraction. This indicates a complete reversal of the natural history of the disease where fat typically replaces muscle tissue. The FDA recently granted SAT-3247 Fast Track, Orphan Drug, and Rare Pediatric Disease designations. These statuses shorten approval timelines. They also grant a lucrative Priority Review Voucher (worth about $200 million USD on the open market) upon success. Wall Street views the equity as heavily discounted. Top-tier healthcare firms like Guggenheim, Leerink, and H.C. Wainwright maintain Strong Buy ratings. Their price targets range from $18.00 to $40.00 (Cantor risk-adj NPV $52/share, non-risk-adj NPV $409/share (includes FSHD)) representing immense upside from the current sub-$10 price point.
0 · Reply
spaceodyssey2001
spaceodyssey2001 Jul. 12 at 2:56 PM
$MSLE
0 · Reply
spaceodyssey2001
spaceodyssey2001 Jul. 12 at 2:01 PM
$MSLE According to Chen Lin of What is Chen Buying? What is Chen Selling? in a July 8 update, "MSLE delivered!" "The data couldn’t be better in my opinion," Chen wrote. "Not only did two patients improve significantly in the MRI, all the four patients are moving in the right direction. I believe if MSLE can deliver good data of the basecamp Q4 and continue improving trailhead data, accelerated approval should be achievable." Chen said he sees the company hitting US$100 per share "by the end of the year if the data are as good as we hope." "I have been there before and can see this happening if the data are positive," the expert said. "The market is giving less than 10% chance of success, I believe it is very mispriced." https://www.streetwisereports.com/article/2026/07/09/biotech-with-muscle-disease-drug-uncovers-results-in-trial-data.html
0 · Reply
spaceodyssey2001
spaceodyssey2001 Jul. 10 at 9:59 PM
$MSLE Satellos Bioscience Delivers Promising DMD Data With Fast Track Win https://www.streetwisereports.com/article/2026/07/09/satellos-bioscience-delivers-promising-dmd-data-with-fast-track-win.html
0 · Reply
nnnuuu
nnnuuu Jul. 9 at 8:20 AM
$MSLE DMD leads to a median life expectancy of 28yo for kids born after 1990 (Broomfield, 2021). the boys in TRAILHEAD follow-up are aged between 21 and 28, to give you an idea of the stage of progressive muscle wasting they are at. any improvement or stability should be applauded at this stage, given the natural history expectation of progressive decline. dataset is small but indicate a strong trend in the right direction across multiple outcomes. This gives me confidence for the upcoming Ph2 BASECAMP readout in a young 7-9 year old cohort in Q4
0 · Reply
Florestan
Florestan Jul. 9 at 7:08 AM
$MSLE I'm sorry for the naysayers, the dataset is simply too coherent, it makes arguing against it a fool's errand. Let's let the data evolve over time and we will see what happens.
0 · Reply
Florestan
Florestan Jul. 9 at 6:37 AM
$MSLE the drug is likely working. The probability of such coherent data without drug effect is very low, given the base rate of 0 for spontaneous FF decline in late stage dmd adults, as demonstrated by all other DMD trials. We are likely in the first inning of a historic rally.
0 · Reply
spaceodyssey2001
spaceodyssey2001 Jul. 8 at 10:40 PM
$MSLE
0 · Reply
mebanks
mebanks Jul. 8 at 5:37 PM
$MSLE , liked this for a run today
0 · Reply
rajbc
rajbc Jul. 8 at 4:40 PM
$MSLE Data suggests that Notch Pathway is safe to inhibit at AAK1 node using SAT-3247, first patient data is looking very good, P2 can be run fast, watch this space!
0 · Reply
Jpickens
Jpickens Jul. 8 at 2:56 PM
$MSLE It’s a wonder that any trader makes any money. They’re so impatient. This is a really good stock. If you would just stop selling it geez lol oh well
0 · Reply
citywokowner
citywokowner Jul. 8 at 2:18 PM
$MSLE Please just run to $30 and i'll be one happy clam.
0 · Reply
Jpickens
Jpickens Jul. 8 at 2:09 PM
$MSLE oh my Lord stop selling fools smh
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 8 at 12:49 PM
$MSLE (+9.6% pre) Satellos’ DMD drug shows better muscle metrics in 4 adults https://ooc.bz/l/107142
0 · Reply
Toptradersam
Toptradersam Jul. 8 at 12:21 PM
$OKLO $VTAK $LUCY $LHAI $MSLE 🚀 Could this be the next AI stock everyone starts talking about? Check out my latest analysis! https://www.youtube.com/watch?v=jrUXaGJEGlk
0 · Reply